• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tobacco Product Use Among Adults - United States, 2017.
Abstract Cigarette smoking harms nearly every organ of the body and causes adverse health consequences, including heart disease, stroke, and multiple types of cancer (1). Although cigarette smoking among U.S. adults has declined considerably, tobacco products have evolved in recent years to include various combustible, noncombustible, and electronic products (1,2). To assess recent national estimates of tobacco product use among U.S. adults aged ≥18 years, CDC, the Food and Drug Administration (FDA), and the National Institutes of Health's National Cancer Institute analyzed data from the 2017 National Health Int...
Source: MMWR Morb Mortal Wkl... - November 9, 2018 Category: Epidemiology Authors: Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-Hayes E, Reyes-Guzman C, Jamal A, Neff L, King BA Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Factors affecting general practitioners' decisions to adopt new prescription drugs - cohort analyses using Australian longitudinal physician survey data.
CONCLUSIONS: Our paper is one of the first to study the relationship between GPs' risk preferences, personality and their decisions to adopt new prescription drugs. Because NOACs are commonly prescribed and considered more cost-effective than their older counterpart, understanding factors affecting physicians' decisions to adopt NOACs has direct policy implications. Our results also highlight that even with universal coverage for prescription drugs, access to new drugs is different among patients, partially because who their doctors are and where they practice. PMID: 30728010 [PubMed - in process]
Source: Australian Family Physician - February 7, 2019 Category: Primary Care Authors: Zhang Y, Méndez SJ, Scott A Tags: BMC Health Serv Res Source Type: research

2019 Alzheimer's disease facts and figures
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report examines the use of brief cognitive assessments by primary care physicians as a tool for improving early detection of dementia. An estimated 5.8 million Americans have Alzheimer's dementia. By mid-century, the number of people living with Alzheimer's dementia in the United States may grow to 13.8 million, fueled in large part by the aging baby boom generation. In 2017, official death certificates ...
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - March 7, 2019 Category: Geriatrics Source Type: research

What ’s the Big Deal about Data in Medtech?
Discussion, “Top 5 Things You Need to Know about the Implantable Internet of Things." Brian Chapman, partner and leader of ZS’s medtech practice of ZS, attributes today’s focus on data to the intersection of two important things: "A general recognition that understanding more and connecting actions with outcomes will provide feedback and understanding that will drive standards of care. This is not new, but as capabilities rise in data collection, aggregation, and synthesize rise, and coupled with machine learning, the promise of data in healthcare is becoming even more ...
Source: MDDI - December 20, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Digital Health Source Type: news

J & amp;J and Apple Begin Enrollment for Heartline Study
In the past few years, Apple has greatly increased its presence in healthcare. The Cupertino, CA-based company has received FDA nods for apps associated with its technology and has found itself in several clinical trials. Most recently, the tech giant is seeing some movement in its partnership with Johnson & Johnson’s Janssen Pharmaceutical unit. The companies just opened enrollment for the Heartline Study, which is designed to explore if the Heartline Study app on iPhone and heart health features on Apple Watch can improve health outcomes, including reducing the risk of stroke, with earlier detection...
Source: MDDI - February 26, 2020 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Cardiovascular Source Type: news

New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
TITUSVILLE, N.J., March 31, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial focus on reaching Black Americans, who are more than twice as likely to be impacted by PAD.1 Janssen has joined forces with leading professional associations, healthcare systems and community organizations to advance equitable care for individuals and communities placed at an...
Source: Johnson and Johnson - March 31, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Implications of Under-Reporting Medication Side Effects: Beta-Blockers in Heart Failure as a Case Example
ConclusionWe conclude that under-reporting perceived side effects of beta-blockers among adults with heart failure is common, is associated with Black race and low education, and may contribute to patient willingness to take additional medication to prevent future medical encounters.
Source: Drugs and Aging - February 17, 2023 Category: Geriatrics Source Type: research

Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease. 6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news

Pages: 1  2  3